Satiogen Pharmaceuticals, Inc.   Report issue

For profit Phase 2
Founded: San Diego CA United States (2007)
Status: Acquired by Mirum Pharmaceuticals, Inc. (2022)

Organization Overview

First Clinical Trial
2016
NCT02871882
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2016

Timeline

NOW
  • Now

Mergers & Acquisitions

Historical Acquisition Tree

Active Ingredients

Drugs in Phase 2 Trials (2)

conjugated bile acids (1 trial)

glucose (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Diabetes Mellitus (Phase 2)

Diabetes Mellitus, Type 2 (Phase 2)

Overweight (Phase 2)

Overview

  • Highest Phase: Phase 2
  • # of Trials: 1
  • # of Trial APIs: 2